Image (7eb8aecb Fbb5 4a6c A8df 5165dddeaf05 01)
Bicalutamide Tablet
Product Images NDC 84508-001
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Bicalutamide (NDC 84508-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pinnacle Life Science Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (7eb8aecb Fbb5 4a6c A8df 5165dddeaf05 02)
This text is not available.*
Image (7eb8aecb Fbb5 4a6c A8df 5165dddeaf05 03)
This text provides information about the comparison of Bicalutamide plus LHRH-A and Fiutamide plus LHRHA based on the progression rate over a certain period (465 days). The data involves the proportion of progression and days to progression for each treatment.*
Desc (7eb8aecb Fbb5 4a6c A8df 5165dddeaf05 04)
This is information about Bicalutamide tablets, USP, containing 50 mg of the active ingredient. The text includes dosage instructions, storage recommendations, and manufacturer details. It also emphasizes child-resistant packaging. The tablets are distributed by Viona Pharmaceuticals Inc. in Granford, NJ.*
Desc (7eb8aecb Fbb5 4a6c A8df 5165dddeaf05 05)
The text contains information about a medication called Bicalutamide USP 50 mg, including its recommended dosage, storage instructions, and a warning to keep it out of the reach of children. The medicine is presented in tablet form and is produced by Pinnacie Life Science Private Limited in Himachal Pradesh, India. The packaging includes color codes, die-cut lines, and a directive not to print on specific areas.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
